Llusern is very pleased to announce that two abstracts assessing the Lodestar UTI testing panel in clinical settings have been published in the American Urology Association’s  Journal of Urology this month.

According to the researchers, Lodestar DX “demonstrated strong performance as a rapid and reliable alternative to standard MC&S and dipstick” and resulted in “meaningful improvements in management.”

The research team from The Royal Berkshire NHS Foundation Trust will be attending the annual AUA congress in Washington from 15-18 May to present both abstracts.

You can read both abstracts here:

Assessing the Lodestar DX uropathogen identifier as a rapid diagnostic alternative to conventional urine culture and dipstick for pre-operative screening

Optimising outpatient urology care with the Lodestar DX rapid urine analyser: Real-time uropathogen identification and antibiotic stewardship.

The Lodestar DX analyser and testing system is registered with the European Patent Office (European Patent Application no: 22732302.9) and the US Patent and Trademark Office (no.18/558,490).